Skip to content

G&A at other companies

CTO
Citius Oncology, Inc.CTOR
$23.63M+953%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$5.71M-5.2%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$3.7M+49.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$6.85M+23.6%
Janux Therapeutics logo
Janux TherapeuticsJANX
$11.13M+13.1%
Vera Therapeutics logo
Vera TherapeuticsVERA
$39.12M+146%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s G&A?
TuHURA Biosciences, Inc. (HURA) reported G&A of $2.3M in Q1 2026.
How has TuHURA Biosciences, Inc.'s G&A changed year-over-year?
TuHURA Biosciences, Inc.'s G&A increased by 13.9% year-over-year, from $2.02M to $2.3M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.